Last updated: November 9, 2026
Nusinersen sodium, marketed as Spinraza by Biogen, remains a major spinal muscular atrophy treatment but is no longer the uncontested standard of care. The drug generated roughly $2 billion in annual revenue at peak and has faced sustained pressure from Roche's Evrysdi and Novartis' one-time gene therapy Zolgensma. Its commercial durability depends on newborn screening, long-term dosing, pediatric and adult uptake, international reimbursement, and Biogen's ability to defend pricing and administration advantages.
What is the current market position of nusinersen sodium?
Nusinersen is an antisense oligonucleotide approved for the treatment of spinal muscular atrophy, or SMA, caused by mutations in the survival motor neuron 1 gene. It modifies SMN2 pre-mRNA splicing to increase production of functional SMN protein (U.S. Food and Drug Administration [FDA], 2016).
Spinraza was the first disease-modifying therapy approved for SMA. It initially benefited from:
- First-to-market status.
- Treatment across infantile, childhood, and adult SMA populations.
- Strong efficacy data in Type 1 SMA.
- Expansion of newborn screening programs.
- Orphan-drug pricing and specialist-center adoption.
- A substantial population of patients already receiving maintenance therapy.
The commercial model is based on repeated intrathecal administration. After loading doses, patients generally receive maintenance treatment every four months. That creates recurring revenue but also exposes the product to administration burden, hospital capacity, anesthesia requirements, and patient switching.
Nusinersen sodium commercial profile
| Attribute |
Spinraza |
| Active ingredient |
Nusinersen sodium |
| Drug class |
Antisense oligonucleotide |
| Sponsor |
Biogen |
| Original developer |
Ionis Pharmaceuticals |
| FDA approval |
December 23, 2016 |
| Primary indication |
SMA caused by SMN1 mutations |
| Administration |
Intrathecal injection |
| Initial loading regimen |
Four doses over approximately two months |
| Maintenance regimen |
One dose every four months |
| U.S. list-price structure |
High-cost loading and maintenance regimen |
| Main competitors |
Evrysdi and Zolgensma |
| Regulatory designation |
Orphan drug |
| Pediatric exclusivity |
Extended U.S. exclusivity into 2024 |
How has nusinersen revenue changed over time?
Nusinersen revenue has moved from rapid launch growth to a mature, declining franchise profile. Biogen reported approximately $2 billion in annual Spinraza revenue around the peak period, followed by lower sales as oral risdiplam and gene therapy entered the market.
| Period |
Market event |
Commercial effect |
| 2016-2017 |
U.S. launch and initial international approvals |
Rapid patient recruitment and high launch growth |
| 2018-2019 |
Broader global reimbursement and diagnosis |
Peak or near-peak franchise revenue |
| 2020-2021 |
COVID-19 treatment interruptions and competing therapies |
Slower starts and greater switching pressure |
| 2022-2023 |
Wider Evrysdi adoption and established Zolgensma use |
Revenue decline and reduced new-patient share |
| 2024 onward |
Mature market with treatment sequencing |
Greater focus on retention, adult patients, and geographic expansion |
Biogen's reported Spinraza revenue fell from approximately $2 billion at peak to roughly $1.7 billion in 2023, according to company annual-report disclosures. The decline has been gradual rather than abrupt because many patients remain on long-term therapy and because Spinraza continues to be used in patients who are unsuitable for, or not selected for, gene therapy (Biogen, 2024).
Revenue sensitivity is driven by four variables:
- The number of diagnosed SMA patients.
- The percentage receiving disease-modifying treatment.
- The share of treated patients using Spinraza.
- The duration of maintenance therapy.
Newborn screening supports patient identification but also intensifies competition. Earlier diagnosis allows families and physicians to compare Spinraza, Evrysdi, and Zolgensma before treatment begins.
Why is Spinraza losing market share?
The central competitive weakness is administration. Spinraza requires repeated lumbar puncture or intrathecal dosing, while Evrysdi is an oral or liquid daily treatment and Zolgensma is administered once.
Spinraza compared with Evrysdi and Zolgensma
| Factor |
Spinraza |
Evrysdi |
Zolgensma |
| Sponsor |
Biogen |
Roche/Genentech |
Novartis |
| Active modality |
Antisense oligonucleotide |
Small-molecule splicing modifier |
AAV gene therapy |
| Administration |
Intrathecal |
Oral or enteral |
One-time intravenous infusion |
| Revenue model |
Recurring maintenance |
Recurring daily treatment |
One-time treatment |
| Main advantage |
Long clinical experience and broad age use |
Less invasive administration |
Potentially durable single treatment |
| Main limitation |
Repeated lumbar puncture |
Daily adherence and chronic cost |
High upfront cost, eligibility and durability questions |
| Competitive risk to Spinraza |
High |
Direct and persistent |
High for newly diagnosed patients |
Evrysdi has captured patients who would otherwise face repeated intrathecal procedures. Its home-administration potential is particularly relevant for older children and adults. Zolgensma has pressured Spinraza most strongly in presymptomatic infants and newly diagnosed young children, although treatment decisions depend on age, clinical status, genetic factors, payer policy, and physician judgment.
Spinraza retains commercial defenses. It has the longest post-launch clinical history among the three products, substantial real-world evidence, and use in patients with anatomy or clinical circumstances that complicate gene therapy or oral treatment. Some patients also switch from gene therapy or Evrysdi to nusinersen because of efficacy, tolerability, access, or physician preference.
What FDA regulatory status applies to nusinersen sodium?
The FDA approved Spinraza in December 2016 under the orphan-drug framework. The approval covered pediatric and adult patients with SMA. The pivotal evidence included a randomized, sham-controlled study in infants and an open-label study in later-onset patients (FDA, 2016).
The regulatory status has several commercial implications:
- Spinraza is an approved disease-modifying treatment, not a symptomatic therapy.
- The label supports broad age use.
- SMA newborn-screening programs increase the addressable diagnosed population.
- Continued post-marketing evidence supports use beyond the original infantile population.
- Pediatric exclusivity extended the period during which certain FDA approval pathways faced additional regulatory protection.
The product does not have biosimilar competition. Nusinersen is a chemically defined antisense oligonucleotide rather than a conventional protein biologic, so a future competitor would more likely pursue an abbreviated generic pathway, a hybrid application, or a full application depending on formulation, route, and regulatory strategy.
When does nusinersen lose U.S. exclusivity?
Nusinersen's FDA orphan-drug exclusivity began with the December 23, 2016 approval and generally ran for seven years, subject to statutory extensions. Pediatric exclusivity added six months after the applicable regulatory exclusivity period.
| Protection category |
Approximate status |
| FDA orphan exclusivity |
December 2016 through December 2023 |
| Pediatric exclusivity |
Extended into June 2024, subject to FDA implementation |
| Patent protection |
Potentially extends beyond regulatory exclusivity |
| Generic entry |
Requires approval of an ANDA or other legally appropriate pathway |
| Biosimilar entry |
Not the expected pathway for nusinersen sodium |
Regulatory exclusivity expiration does not automatically authorize generic launch. A generic applicant must obtain FDA approval and address listed patents, clinical or pharmaceutical equivalence, manufacturing requirements, and any applicable litigation stay.
What patents protect Spinraza and nusinersen sodium?
Spinraza's patent estate is built around several technical layers rather than a single product patent. Relevant categories include:
- Antisense oligonucleotide sequences targeting SMN2.
- Chemical modifications that improve nuclease resistance and pharmacologic performance.
- Splicing-modulation mechanisms.
- Pharmaceutical compositions.
- Manufacturing and purification processes.
- Dosing regimens and treatment methods.
- Formulation and injectable-product characteristics.
Ionis developed nusinersen and licensed rights to Biogen. Biogen has commercialized Spinraza globally under its collaboration and licensing arrangements with Ionis. The economic structure includes Biogen product sales and contractual obligations to Ionis, including royalties or other payments under the parties' agreements (Ionis Pharmaceuticals, 2012; Biogen, 2024).
Patent durability depends on the specific claim, jurisdiction, patent-term adjustment, terminal disclaimers, and Orange Book listing. Regulatory exclusivity has ended, but selected patent claims may continue to affect U.S. generic timing. In Europe and other markets, the analysis depends on national validation, supplementary protection certificates, and local enforcement.
How strong is the Spinraza patent estate?
The estate is commercially meaningful but less secure than it was during the launch period.
Its strengths are:
- Multiple claim categories surrounding sequence, chemistry, use, and manufacture.
- Early filing dates associated with antisense technology.
- Biogen and Ionis ownership and enforcement resources.
- A complex product-development history that can increase generic development costs.
Its weaknesses are:
- Some core claims face expiration or validity challenges over time.
- A generic applicant may avoid particular method-of-use claims.
- Product-by-process and formulation claims may provide narrower protection than composition claims.
- The product's commercial decline reduces the value of prolonged litigation relative to market size.
Are there Paragraph IV challenges to nusinersen?
A Paragraph IV challenge is possible after an ANDA applicant identifies an Orange Book patent as invalid, unenforceable, or not infringed. Publicly documented commercial impact from a major U.S. Paragraph IV dispute involving Spinraza has been limited compared with high-profile small-molecule products.
The practical barriers are substantial:
- Intrathecal delivery must be reproduced reliably.
- Oligonucleotide identity, impurity profile, potency, and stability require specialized manufacturing.
- Bioequivalence may not be straightforward for a complex injectable oligonucleotide.
- A challenger must assess sequence, chemical modification, composition, formulation, and process claims.
- A successful patent challenge would still require FDA approval and commercial manufacturing scale.
Generic entry is therefore more likely to be delayed by technical development and litigation economics than by regulatory exclusivity alone. The risk is higher in markets where patent enforcement is weaker or where local approval pathways permit earlier competition.
What manufacturing and intellectual-property barriers affect generic entry?
Nusinersen is not a simple tablet or conventional injectable. It is a chemically modified oligonucleotide requiring controlled synthesis, purification, characterization, sterile formulation, and intrathecal-product quality controls.
Key manufacturing barriers include:
- Reproducible oligonucleotide synthesis at commercial scale.
- Control of truncated sequences and other process impurities.
- Demonstration of batch consistency.
- Sterility and endotoxin control.
- Analytical comparability for a complex molecular mixture.
- Specialized packaging and stability validation.
- Clinical or pharmacologic evidence sufficient for the selected regulatory pathway.
These barriers increase development costs and reduce the number of potential entrants. They do not eliminate generic risk, particularly after orphan and pediatric exclusivity have expired.
How do licensing deals affect nusinersen economics?
Biogen's relationship with Ionis is central to the product's economics. Ionis originated the antisense technology and nusinersen program, while Biogen assumed major development, regulatory, and commercial responsibilities. The arrangement gave Biogen access to a rare-disease franchise and gave Ionis continuing economic participation without bearing the full global commercialization burden.
The deal affects valuation in two ways:
- Biogen's reported Spinraza revenue is not equal to product-level operating profit because royalties and collaboration payments reduce net economics.
- Ionis retains an economic interest in the product, so franchise decline affects both companies.
Licensing economics also influence lifecycle strategy. Biogen has incentives to preserve the existing patient base, expand evidence in adults and presymptomatic patients, and defend access in markets where treatment switching can materially reduce recurring revenue.
What generic launch scenarios exist for nusinersen?
The most plausible U.S. scenarios are:
Scenario 1: No near-term generic launch
A technically complex product, limited market growth, and remaining patent claims could deter investment. Spinraza would continue as a mature branded therapy with declining but durable revenue.
Scenario 2: First generic launch after patent settlement
A challenger could settle with Biogen and Ionis for a later licensed entry date. The launch would likely begin with limited supply and price discounting rather than immediate full substitution.
Scenario 3: Litigation-driven early entry
An ANDA applicant could challenge core claims and launch after a favorable judgment or settlement. This would create the highest revenue shock, particularly for payer-controlled segments.
Scenario 4: Non-generic competitive substitution
Evrysdi and Zolgensma may continue to reduce Spinraza use without any generic launch. This is the most important existing source of market erosion.
What is the geographic market outlook for nusinersen?
The United States remains economically important, but international markets determine a substantial portion of long-term volume. Uptake varies according to:
- Newborn-screening coverage.
- National health technology assessment.
- Hospital funding.
- Intrathecal-treatment capacity.
- Risk-sharing agreements.
- Availability of Evrysdi and Zolgensma.
- Local patent and regulatory rules.
In lower-income markets, access and reimbursement can limit treatment more than patent expiry. In Europe, price negotiation and country-specific reimbursement can compress net sales even when patient numbers rise. Emerging markets may offer volume growth but generally at lower net prices and with more demanding public procurement processes.
What is the long-term financial trajectory for nusinersen?
Spinraza is best modeled as a mature specialty franchise rather than a growth product. The revenue base should remain supported by:
- Existing chronic patients.
- Adult and later-onset SMA treatment.
- Presymptomatic diagnosis.
- Patients unsuitable for gene therapy.
- Markets with limited access to competing products.
The main downside factors are:
- New-patient preference for oral therapy.
- One-time gene therapy use in infants.
- Payer pressure on chronic high-cost treatment.
- Intrathecal administration burden.
- Eventual generic or follow-on competition.
- Reduced treatment switching back to Spinraza after competitor initiation.
A base-case commercial model would assume gradual revenue erosion rather than immediate collapse. The most severe downside occurs if early-diagnosed infants predominantly receive Zolgensma, older patients shift to Evrysdi, and a generic or authorized competitor enters before the existing patient population turns over.
Key Takeaways
- Nusinersen sodium remains a major SMA therapy but has transitioned from launch growth to franchise defense.
- Spinraza revenue peaked near $2 billion annually and has declined to approximately $1.7 billion in recent reporting periods.
- Evrysdi is the strongest direct competitive threat because it avoids repeated intrathecal administration.
- Zolgensma is the largest threat for newly diagnosed infants and presymptomatic patients.
- U.S. orphan and pediatric exclusivity protections have expired or ended, but patent claims and regulatory requirements still influence generic timing.
- The product has no biosimilar pathway in the conventional sense.
- Ionis retains economic importance through its licensing relationship with Biogen.
- The strongest remaining commercial defenses are long-term clinical evidence, broad age use, established treatment centers, and patients who are not candidates for gene therapy or oral treatment.
- Manufacturing complexity limits the number of credible generic entrants but does not remove long-term generic risk.
FAQs About Nusinersen Sodium Market and Patent Exposure
Is nusinersen sodium still commercially viable after Evrysdi and Zolgensma?
Yes. The product remains commercially viable because many patients continue long-term therapy, and some patients are not suitable for gene therapy or prefer an established intrathecal treatment.
Does nusinersen sodium have biosimilar competition?
No conventional biosimilar competition exists. Future competitors would more likely pursue generic, hybrid, or full regulatory pathways for a complex antisense injectable.
Is Spinraza more expensive than Evrysdi?
The answer depends on list price, negotiated discounts, treatment duration, administration costs, and patient age. Spinraza has high loading and maintenance costs, while Evrysdi creates recurring daily-treatment costs.
Can patients switch from Zolgensma to Spinraza?
Treatment decisions are individualized. Patients may receive nusinersen after gene therapy when clinical response, durability, safety, or disease progression raises a treatment question, subject to physician and payer policies.
Will a nusinersen generic immediately eliminate Biogen's revenue?
No. Entry would depend on approval, patent outcomes, manufacturing capacity, payer substitution rules, and physician adoption. A generic would likely reduce price and new-patient share before eliminating the established branded base.
References
Biogen. (2024). 2023 annual report. https://investors.biogen.com/financial-information/annual-reports
Ionis Pharmaceuticals. (2012). Ionis Pharmaceuticals and Biogen Idec announce strategic collaboration to develop and commercialize antisense drugs. https://ir.ionispharma.com
U.S. Food and Drug Administration. (2016). SPINRAZA (nusinersen) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209531lbl.pdf
U.S. Food and Drug Administration. (2020). Evrysdi (risdiplam) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213535s000lbl.pdf
U.S. Food and Drug Administration. (2022). Zolgensma (onasemnogene abeparvovec-xioi) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125694s042lbl.pdf
